85 related articles for article (PubMed ID: 22910440)
41. Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab.
Claret L; Gupta M; Han K; Joshi A; Sarapa N; He J; Powell B; Bruno R
J Clin Pharmacol; 2014 Mar; 54(3):253-7. PubMed ID: 24122760
[TBL] [Abstract][Full Text] [Related]
42. Bevacizumab for non-small-cell lung cancer.
Sculier JP; Meert AP; Paesmans M
N Engl J Med; 2007 Mar; 356(13):1373-4; author reply 1374-5. PubMed ID: 17396306
[No Abstract] [Full Text] [Related]
43. Bevacizumab for non-small-cell lung cancer.
Oxnard GR
N Engl J Med; 2007 Mar; 356(13):1373; author reply 1374-5. PubMed ID: 17396305
[No Abstract] [Full Text] [Related]
44. Efficacy of motesanib diphosphate in non-small-cell lung cancer.
Rijavec E; Genova C; Barletta G; Biello F; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Boccardo F; Grossi F
Expert Opin Pharmacother; 2014 Aug; 15(12):1771-80. PubMed ID: 25032887
[TBL] [Abstract][Full Text] [Related]
45. Reporting of subset analysis: where do we draw the line?
Goel S
J Clin Oncol; 2008 Apr; 26(12):2062-3; author reply 2064-5. PubMed ID: 18421065
[No Abstract] [Full Text] [Related]
46. Exploratory modeling and simulation to support development of motesanib in Asian patients with non-small cell lung cancer based on MONET1 study results.
Claret L; Bruno R; Lu JF; Sun YN; Hsu CP
Clin Pharmacol Ther; 2014 Apr; 95(4):446-51. PubMed ID: 24440965
[TBL] [Abstract][Full Text] [Related]
47. Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): impressions from MONET (the motesanib NSCLC efficacy and tolerability study).
Morgensztern D; Herbst RS
J Clin Oncol; 2012 Aug; 30(23):2805-8. PubMed ID: 22753916
[No Abstract] [Full Text] [Related]
48. Cemiplimab Plus Chemotherapy Could Be a First-Line Option for Advanced and Metastatic NSCLC: Results From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
Zhao B; Qi H; Wu J; Ma W
J Thorac Oncol; 2023 Jul; 18(7):e72-e73. PubMed ID: 37348996
[No Abstract] [Full Text] [Related]
49. Assessing non-inferiority with time-to-event data via the method of non-parametric covariance.
Zhang X; Xu J; He J
Stat Methods Med Res; 2013 Jun; 22(3):346-60. PubMed ID: 21705437
[TBL] [Abstract][Full Text] [Related]
50. Models of excellence: improving oncology drug development.
Sharma MR; Maitland ML; Ratain MJ
Clin Pharmacol Ther; 2012 Nov; 92(5):548-50. PubMed ID: 23085878
[TBL] [Abstract][Full Text] [Related]
51. Too Good to be True?
Sebastian M; Stratmann JA; Eberhardt WEE
J Thorac Oncol; 2021 Apr; 16(4):507-508. PubMed ID: 33781437
[No Abstract] [Full Text] [Related]
52. C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework.
Nassar YM; Ojara FW; Pérez-Pitarch A; Geiger K; Huisinga W; Hartung N; Michelet R; Holdenrieder S; Joerger M; Kloft C
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001689
[TBL] [Abstract][Full Text] [Related]
53. Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma.
Chen T; Zheng Y; Roskos L; Mager DE
J Pharmacokinet Pharmacodyn; 2023 Aug; 50(4):251-265. PubMed ID: 36906878
[TBL] [Abstract][Full Text] [Related]
54. Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
Bruno R; Marchand M; Yoshida K; Chan P; Li H; Zou W; Mercier F; Chanu P; Wu B; Lee A; Li C; Jin JY; Maitland ML; Reck M; Socinski MA
Clin Cancer Res; 2023 Mar; 29(6):1047-1055. PubMed ID: 36595566
[TBL] [Abstract][Full Text] [Related]
55. Bayesian forecasting of tumor size metrics and overall survival.
Krishnan SM; Friberg LE
CPT Pharmacometrics Syst Pharmacol; 2022 Dec; 11(12):1604-1613. PubMed ID: 36194478
[TBL] [Abstract][Full Text] [Related]
56. Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel.
Krishnan SM; Friberg LE; Bruno R; Beyer U; Jin JY; Karlsson MO
CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1255-1266. PubMed ID: 34313026
[TBL] [Abstract][Full Text] [Related]
57. Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models.
Bruno R; Bottino D; de Alwis DP; Fojo AT; Guedj J; Liu C; Swanson KR; Zheng J; Zheng Y; Jin JY
Clin Cancer Res; 2020 Apr; 26(8):1787-1795. PubMed ID: 31871299
[TBL] [Abstract][Full Text] [Related]
58. Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A.
Han K; Claret L; Piao Y; Hegde P; Joshi A; Powell JR; Jin J; Bruno R
CPT Pharmacometrics Syst Pharmacol; 2016 Jul; 5(7):352-8. PubMed ID: 27404946
[TBL] [Abstract][Full Text] [Related]
59. Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer.
Zecchin C; Gueorguieva I; Enas NH; Friberg LE
Br J Clin Pharmacol; 2016 Sep; 82(3):717-27. PubMed ID: 27136318
[TBL] [Abstract][Full Text] [Related]
60. A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use.
Jonsson F; Ou Y; Claret L; Siegel D; Jagannath S; Vij R; Badros A; Aggarwal S; Bruno R
CPT Pharmacometrics Syst Pharmacol; 2015 Dec; 4(12):711-9. PubMed ID: 26904385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
